Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has announced positive topline results from its pivotal Phase 3 APPROACH trial of HLP003 (deuterated psilocin) as an adjunctive treatment for adults with major depressive disorder (MDD). The randomized, double-blind, placebo-controlled study enrolled 222 participants and met its primary, key secondary, and other secondary endpoints, according to the company's press release.
At the primary six-week endpoint, HLP003 produced a 19.5-point reduction from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS), compared with 11.9 points for placebo, a 7.6-point difference (p<0.0001). Significant improvements were observed as early as Day 2, and treatment benefits were maintained through Week 12, with a placebo-adjusted difference of 7.0 points (p<0.0001). HLP003 also demonstrated statistically significant improvements in response and remission rates, with 50.9% of treated participants achieving remission at Week 6 compared with 18.2% receiving placebo.
The treatment was generally well tolerated, with most adverse events mild to moderate and transient, although three treatment-related serious adverse events were reported. No new safety signals were identified. APPROACH is the first of three studies in the company's PARADIGM Phase 3 program, which also includes the ongoing EMBRACE pivotal trial and EXTEND long-term extension study. Helus Pharma expects to report topline results from EMBRACE in the fourth quarter of 2027 as it advances HLP003 toward potential regulatory approval and commercialization.
For investors, the positive Phase 3 data could represent a significant milestone for Helus Pharma, which is developing novel serotonergic agonists (NSAs) to address the large unmet need in depression and anxiety. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, underscoring its potential to offer a new treatment paradigm. The company, founded in 2019 and operating in Canada, the United States, the United Kingdom, and Ireland, aims to improve the treatment landscape with durable improvements in mental health.
The announcement was disseminated by NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution. These services help companies like Helus Pharma reach a wide audience of investors and journalists.
The positive results from APPROACH could have broader implications for the mental health treatment landscape, as MDD affects millions worldwide and current therapies often fall short. If HLP003 continues to demonstrate efficacy and safety in the ongoing EMBRACE trial, it could become a valuable adjunctive treatment option. However, investors should note that the trial is not yet complete, and regulatory approval is not guaranteed. For more details, the full press release is available at https://ibn.fm/IloYS, and additional information about Helus Pharma can be found at www.helus.com. The company's latest news and updates are available in its newsroom.

